您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Covance Reports Second Quarter Revenue of $475M and EPS of $0.49; Updates Full-Year Financial Targets(9)
本文章共23214字,分15页,当前第9页,快速翻页:


  of business:
  ----------------------------------------
  Income before taxes and equity investee
  earnings                                        $93,602        $115,068
  Taxes on income                                  $23,469          $32,171
  Net income                                      $70,806          $82,859
  Basic earnings per share                          $1.11            $1.30
  Diluted earnings per share                        $1.09            $1.29



                            COVANCE INC.
                      CONSOLIDATED BALANCE SHEETS
                  JUNE 30, 2010 and DECEMBER 31, 2009
                        (Dollars in thousands)

                                              June 30    December 31
                                                  2010        2009
                                                  ----        ----
                                            (UNAUDITED)
  ASSETS
  Current Assets:
    Cash & cash equivalents                    $290,845    $289,469
    Accounts receivable, net                    281,106      285,119
    Unbilled services                          114,109      97,279
    Inventory                                    77,624      80,926
    Deferred income taxes                        34,706      31,512

 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  Commonwealth Biotechnologies, Inc. Provi

Quintiles Announces New European Headqua

FDA Approves Drug for Chronic Drooling i

Abbott's Simcor ( niacin extended-releas

Abraxis BioScience and Specialised Thera

Shionogi Inc. Announces FDA Approval of

Researchers Solve Mystery of Uner Tan Sy

WaferGen Announces Purchase of SmartChip

Plant Compound Resveratrol Shown to Supp

New pathway to Parkinson's and Alzheimer

deCODE Shows how Genetic Risk of Kidney

相关评论

    
本文章所属分类:首页 研发动态